Clinical trial · Observational

Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J

Sample Analysis for Terminated Protocol 00-C-0070, Pediatric Phase I Trial of Arsenic Trioxide

NCT00899015CI-TRIAL-00006518completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying bone marrow and blood samples from patients with leukemia or lymphoma treated with arsenic trioxide may help doctors learn more about cancer. PURPOSE: This research study is assessing arsenic trioxide in young patients with recurrent or refractory leukemia or lymphoma who were treated on clinical trial NCI-00-C-0070J.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Leukemia	Leukemia	ONTOLOGY_EXACT	0.90
Lymphoma	Lymphoma	ONTOLOGY_EXACT	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
pharmacological study	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (3)

measure
Pharmacokinetics (PK)
measure
Pharmacodynamics (PD)
measure
Correlation of PK and PD with clinical parameters, such as age, gender, and dose

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 2 Years
Maximum age: 21 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Histologically confirmed leukemia or lymphoma refractory to standard curative treatment regimens

  * No meningeal leukemia or lymphoma
  * No HIV-related lymphoma
  * No lymphoproliferative diseases
* Received treatment on protocol NCI-00-C-0070J
* Bone marrow or peripheral blood and serum samples collected during treatment on NCI-00-C-0070J are available

PATIENT CHARACTERISTICS:

* See NCI-00-C-0070J

PRIOR CONCURRENT THERAPY:

* See NCI-00-C-0070J

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: —
Primary completion: —
Completion: Feb 1, 2008
First posted: May 12, 2009
Last update posted: Mar 16, 2012
Enrollment: 23 (estimated)
Lead sponsor: National Institutes of Health Clinical Center (CC) NIH
Collaborators: National Cancer Institute (NCI)
Keywords: recurrent childhood acute myeloid leukemia, childhood acute promyelocytic leukemia (M3), recurrent childhood acute lymphoblastic leukemia, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent/refractory childhood Hodgkin lymphoma, childhood chronic myelogenous leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative

Data updated 22 days agoSource updated Mar 16, 2012source: clinicaltrials

Locations

Locations by country (0)

No location posted.

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.